1. A method of reducing the duration or severity of an inflammatory immune response in a subject, comprising administering to said subject a pharmaceutical composition containing carboxylated particles, with no attached peptides or antigenic molecules in said particles. The method according to claim 1, characterized in that the carboxylated particles are polylactic-co-glycolic acid (PLGA) particles, polystyrene particles or diamond particles. The method according to claim 1, characterized in that the diameter of said carboxylated particles is between about 0.1 microns to about 10 microns, between about 0.3 microns to about 5 microns, between about 0.5 microns to about 3 microns, between about 0.5 μm to about 1 μm or about 0.5 μm. 4. The method according to claim 1, characterized in that the subject has an autoimmune disorder, such as multiple sclerosis, scleroderma, type I diabetes, rheumatoid arthritis, thyroiditis, systemic lupus erythematosus, Raynaud's syndrome, Sjogren's syndrome, autoimmune uveitis, autoimmune myocarditis or Crohn’s disease, has ischemic reperfusion injury, atherosclerosis, suffered from myocardial infarction, is a transplant recipient, has psoriasis or dermatitis, or suffers from an allergic disorder such as eczema, asthma, allergic rhinitis, or hype rchuvstvitelnost kozhi.5. The method according to claim 1, characterized in that the composition is administered orally, nasally, intravenously, intramuscularly, through the eye, percutaneously or subcutaneously. A method of treating a viral or bacterial infection in a subject, comprising administering to said subject a pharmaceutical composition comprising carboxylated frequent1. Способ снижения продолжительности или тяжести воспалительного иммунного ответа у субъекта, включающий введение указанному субъекту фармацевтической композиции, содержащей карбоксилированные частицы, при этом прикрепленные пептиды или антигенные молекулы в указанных частицах отсутствуют.2. Способ по п.1, отличающийся тем
